By: Tanya Thomas on July 12, 2010 at 10:39 AM Vaccine manufacturers in India and other developing nations can produce a lower-cost HPV vaccine despite the complicated array of patent protections on the technology, according to an Indian-origin scientist at the Duke Institute for Genome Sciences and Policy. At a cost of at least 300dollars […]
HPV DNA testing over 50 percent more sensitive than cytology testing
Science Centric | 9 July 2010 10:46 GMT HPV DNA testing for precancers and cervical cancers is over 50 per cent more sensitive than cytology testing for the same conditions a community-based study in Mexico has revealed. Results of the largest HPV DNA primary screening study ever to be performed in a Latin American country […]
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24—45 years: a randomised, double-blind trial
The Lancet, Volume 373, Issue 9679, Pages 1949 – 1957, 6 June 2009 doi:10.1016/S0140-6736(09)60691-7: Munoz, et al Background: Although the peak incidence of human papillomavirus (HPV) infection occurs in most populations within 5—10 years of first sexual experience, all women remain at risk for acquisition of HPV infections. We tested the safety, immunogenicity, and […]
Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting Infection
A Randomized Trial JAMA. 2007;298:743-753. Main Outcome Measures Presence of HPV DNA was determined in cervical specimins by a molecular hybridization assay using chemiluminescence with HPV RNA probes and by polymerase chain reaction using SPF10 primers and a line probe assay detection system before vaccination and by polymerase chain reaction after vaccination. We compared rates of […]
GARDASIL: Prophylactic Human Papillomavirus Vaccine Development – From Bench Top to Bed-side
L Shi1, HL Sings1, JT Bryan1, B Wang1, Y Wang1, H Mach1, M Kosinski1, MW Washabaugh1, R Sitrin1 and E Barr1 February 2007 GARDASILs (Merck, Whitehouse Station, NJ) is a non-infectious recombinant, quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid proteins of human papillomavirus (HPV) types 6, 11, […]
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 21
- Next Page »
